Pfizer: PARP-inhibitor Combination Treatments in Prostate Cancer

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:

• Increasing the understanding of the mechanism of action, biological and clinical rationale for PARP-inhibitor combinations as potential treatments for prostate cancer.
• PARP-inhibitor combinations with androgen receptor targeted therapies.
• The evolving paradigm of the potential treatment of mCRPC with future PARP-inhibitor combinations.
• Optimal therapy management for PARP-inhibitor combinations in prostate cancer.

Funding: up to $250,000.

https://cdn.pfizer.com/pfizercom/2023-03/2023%20PARP-inhibitor%20Combination%20Treatments%20in%20Prostate%20Cancer.pdf?PzixcfMZ_eQJvrdRyzhVPSuWwJFdXEc6=

https://www.pfizer.com/purpose/independent-grants/competitive-grants